Company Encyclopedia
View More
name
Livanova
LIVN.US
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products and therapies for neurological and cardiac conditions worldwide. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related accessories. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; and devices that deliver neuromodulation therapy for treating difficult-to-treat depression and drug-resistant epilepsy.
1.407 T
LIVN.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Health Care EquipmentIndustry
Industry Ranking53/171
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-17.63%E
    • Profit Margin-16.12%D
    • Gross Margin68.78%A
  • Growth ScoreC
    • Revenue YoY8.63%B
    • Net Profit YoY-1018.36%E
    • Total Assets YoY1.41%C
    • Net Assets YoY-11.66%E
  • Cash ScoreD
    • Cash Flow Margin-620.25%E
    • OCF YoY8.63%B
  • Operating ScoreC
    • Turnover0.53C
  • Debt ScoreC
    • Gearing Ratio54.75%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    LivaNova Highlights CORE-VNS Study Showing VNS Therapy Reduces Seizure Frequency and Healthcare Costs in Drug-Resistant Epilepsy

    LivaNova PLC will present eight scientific posters at the American Epilepsy Society Annual Meeting, showcasing real-world evidence from the CORE-VNS study on VNS Therapy for Drug-Resistant Epilepsy. The study indicates reductions in seizure frequency, hospitalizations, emergency visits, and overall healthcare costs. The results will be available to attendees and on the AES website.

    Reuters·
    US
    LIVN
    +0.96%
    Reuters·
    US
    LIVN
    +0.96%

    LivaNova Names Lucile Blaise Global Head of Commercialization for Obstructive Sleep Apnea

    LivaNova PLC has appointed Lucile Blaise as Global Head of Commercialization for Obstructive Sleep Apnea, effective December 1. Blaise joins the Executive Leadership Team, reporting to CEO Vladimir Makatsaria, bringing over 25 years of medtech experience.

    Reuters·
    US
    LIVN
    +0.96%
    Reuters·
    US
    LIVN
    +0.96%

    LivaNova (LIVN) Is Up 5.5% After Medicare Boosts VNS Therapy Reimbursement—Has the Bull Case Changed?

    LivaNova's stock rose 5.5% after the U.S. Centers for Medicare & Medicaid Services increased reimbursement rates for VNS Therapy, effective January 2026. This change reduces financial barriers for hospitals, potentially boosting adoption of the therapy. The CMS decision, influenced by positive results from the CORE-VNS study, is seen as a catalyst for LivaNova's growth, despite long-term pricing pressures. LivaNova's revenue is projected to reach $1.6 billion by 2028, with a fair value estimate of $69.10 per share, reflecting an 8% upside.

    Simplywall·
    US
    LIVN
    +0.96%
    Simplywall·
    US
    LIVN
    +0.96%

    Stocks With Rising Relative Price Strength: LivaNova

    LivaNova sees its Relative Strength Rating hit the 80-plus level.

    MSN·
    US
    LIVN
    +0.96%
    MSN·
    US
    LIVN
    +0.96%

    Primecap Management Co. CA Acquires 32,942 Shares of LivaNova PLC $LIVN

    Primecap Management Co. CA increased its holdings in LivaNova PLC by 0.7% in Q2, owning 8.50% of the company. Analysts have upgraded LivaNova's stock, with price targets raised to $70.00, reflecting positive sentiment. LivaNova reported strong quarterly earnings, with revenue up 12.5% year-over-year, and set FY 2025 EPS guidance at 3.800-3.90.

    Market Beat·
    US
    LIVN
    +0.96%
    Market Beat·
    US
    LIVN
    +0.96%
    © 2025 Longbridge｜Disclaimer